Scarica l'app Stockscreener
5.69
0.70%
-0.04
Dopo l'orario di chiusura:
5.68
-0.01
-0.18%
Precedente Chiudi:
$5.73
Aprire:
$5.7
Volume 24 ore:
50,244
Relative Volume:
0.61
Capitalizzazione di mercato:
$71.45M
Reddito:
$4.28M
Utile/perdita netta:
$-7.28M
Rapporto P/E:
-6.985
EPS:
-0.8146
Flusso di cassa netto:
$-6.17M
1 W Prestazione:
-6.26%
1M Prestazione:
-17.18%
6M Prestazione:
-9.83%
1 anno Prestazione:
+133.20%
Intervallo 1D:
$5.57
$5.7252
Intervallo di 1 settimana:
$5.57
$6.08
Portata 52W:
$2.21
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Nome
Neuraxis Inc
Settore
Industria
Telefono
(812) 689-0791
Indirizzo
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
5.69 | 71.96M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Borsa (NRXS) Ultime notizie
NRXS Forecast & Price Target - TradingKey
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
Neuraxis Inc. (NRXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Neuraxis (NRXS) Q2 2026 Earnings: EPS Beats Its Estimate in the Latest Session; Price Move: Shares Finish 1.91% Down in the Current UpdateEarnings Expansion Phase - vinanet.vn
NeurAxis Earnings Call Signals High Growth, High Hurdles - TipRanks
NeurAxis Enhances Executive and Director Equity Compensation - TipRanks
Neuraxis (NRXS) grants CEO 199K instantly vesting stock units - Stock Titan
NeurAxis (NRXS) Institutional Ownership 2026 - MarketBeat
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up - NewsBreak: Local News & Alerts
Neuraxis (NRXS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 32%Performance Review - vinanet.vn
NRXS Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 32% Stock SurgeEarnings Per Share - vinanet.vn
Neuraxis Inc. (NRXS) Q2 2026 Earnings: Narrower Loss Beats Expectations as Stock Holds SteadyStrong Earnings Momentum - vinanet.vn
NRXS Q2 2026 Earnings: 41.79% EPS Beat Signals Cost Discipline, Yet Shares Slip 1.26%Return On Assets - vinanet.vn
NeurAxis revenues up 116% to USD 1.9M in Q2 2026 - Medical Buyer
NeurAxis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Could NeurAxis (NASDAQ:NRXS) Reshape Nasdaq Composite Focus? - Kalkine Media
Transcript : NeurAxis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
NeurAxis (NASDAQ:NRXS): What Could Today’s Update Reveal About Pediatric Therapy Adoption And Reimbursement? - Kalkine Media
NRXS: Q2 revenue up 116% YoY, gross margin at 85.9%, with payer coverage and VA expansion driving growth - TradingView
Earnings call transcript: NeurAxis falls on Q2 2026 EPS miss despite 116% revenue growth - Investing.com
NeurAxis reports 116% revenue growth in second quarter 2026 By Investing.com - Investing.com Nigeria
NeurAxis reports 116% revenue growth in second quarter 2026 - Investing.com
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth - The Manila Times
NRXS: Q2 2026 revenue surged 116% year-over-year, with gross margin up to 85.9% and strong cash position - TradingView
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NeurAxis (NYSE American: NRXS) doubles sales yet warns on going concern - Stock Titan
Earnings To Watch: Neuraxis Inc (NRXS) Q2 2026 -- GF Value Sees 55% Downside - Yahoo Finance
NeurAxis, Inc. (NRXS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
NeurAxis宣佈爲IB-Stim PENFS療法增加美國中大西洋地區的覆蓋範圍，將服務擴展至超過500,000人 - Moomoo
Neuraxis Expands Payer Coverage for Percutaneous Electrical Nerve Field Stimulation and Ib-Stim Treatment - marketscreener.com
NeurAxis expands insurance coverage for its IB-Stim neuromodulation device, adding 500,000 covered lives. - pluang.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Neuraxis Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats Consensus by 7.12%Dividend Cut Risk - vinanet.vn
NRXS|Neuraxis Inc|Price:6.735|Chg%:+0.485 - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRXS Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEPS Estimate Trend - vinanet.vn
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 - The Manila Times
NeurAxis, Inc. to Report Second Quarter 2026 Financial Results on August 11 and Host Conference Call - quiverquant.com
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NRXS|Neuraxis Inc|Price:6.800| - TradingKey
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Neuraxis, Inc. Revenue Breakdown – AMEX:NRXS - TradingView
Form S-3 Neuraxis Inc For: 24 July By Investing.com - Investing.com South Africa
Neuraxis Inc. (NRXS) Posts Modest Gains, Testing Key LevelsValue Area High - Vinanet
NRXS Q1 2026 Earnings: EPS Beat as Narrower-Than-Expected Losses Offset by Stock DeclineEarnings Yield Analysis - vinanet.vn
NRXS Q1 2026 Earnings: Narrower Loss Surprises, but Stock Declines 2.87%Earnings Forecast Report - vinanet.vn
Neuraxis Inc Azioni (NRXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Capitalizzazione:
|
Volume (24 ore):